Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs

August 22, 2019

Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.

Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.

Transcript

How does real-world data’s incorporation of the patient perspective allow for confirmatory information regarding newly approved drugs?

One of things I think real-world evidence does is that it provides confirmatory information in terms of new treatments, but also it provides the opportunity to collect the perspective of what the patient is going through. So, something that is very exciting is so-called patient-reported outcomes, and we’re developing the capacity with our EMR [electronic medical record], that not only can we describe how the patient did, talk about their response, progression, their improvement, but also we can collect their impression of how their treatment, how they’re feeling, are they have side effects? And this is coincidental with the interests and the appreciation that the better you can follow your patients, the better your patients have an opportunity to communicate with their providers, the better care is achieved. This is again a situation where incentives are aligned. At the end of the day, better improving patient care and also you can collect information as outcomes researchers to be able to share that information with others.